Archives
-
Ginsenoside Rg1 for Neuroimmune Research
2026-09-27
Build a reproducible neuroimmune workflow around Ginsenoside Rg1, from compound handling to behavioral, cytokine, synaptic, and gut-barrier readouts. A 2025 mouse study provides a defined prolonged-isoflurane model and points to regulatory T cells as a testable mechanism—not a clinical treatment claim.
-
Anisomycin Workflows for JNK-Linked Apoptosis
2026-09-25
Use Anisomycin to test JNK-linked stress signaling and apoptosis with a workflow that separates rapid pathway readouts from later cell-death outcomes. A 2025 social-memory study offers a useful contrast: it shows why pathway-specific controls matter, but does not establish Anisomycin as a memory mechanism.
-
Arachidonic Acid Workflows for Immune Research
2026-09-25
Use Arachidonic Acid to probe how lipid substrate availability shapes eicosanoid output and immune-cell responses. This workflow pairs pathway readouts with B-cell measurements, while separating practical assay recommendations from findings reported in a recent vaccination study.
-
Hypoxia Duration Drives Urothelial Inflammation In Vitro
2026-09-24
A 2024 in vitro study found that short enzyme-induced hypoxia stabilized HIF-1α and increased nitric oxide activity in rat urothelial cells, while longer exposure was needed to increase caspase-1 activity. Antioxidant and verapamil interventions support a duration-dependent ROS/TXNIP/NLRP3 interpretation, while leaving important questions about pathway specificity and translation to bladder outlet obstruction.
-
HCAR3 Structures Reveal Agonist Recognition and Selectivity
2026-09-24
Cryo-EM structures of agonist-bound HCAR3 and HCAR2, paired with cAMP assays, identify pocket features associated with ligand recognition and receptor preference. The findings provide a structural basis for studying HCAR3-selective signaling, while showing why Acifran should not be treated as an HCAR3-selective ligand on the evidence presented.
-
Filipin III for Mapping Hepatic Cholesterol Homeostasis
2026-09-23
Filipin III can reveal where membrane-accessible cholesterol is distributed, but its signal is not a direct measure of total liver cholesterol. This article connects Filipin-based imaging to Caveolin-1 research in MASLD and explains how to design and interpret spatial assays without overreading them.
-
SIS3: Strategic Control of TGF-β/Smad3 Signaling
2026-09-23
A translational perspective on SIS3 as a selective Smad3 inhibitor, connecting fibrosis research and renal disease models with emerging evidence that canonical TGF-β/SMAD3 signaling can be epigenetically amplified in early-stage lung adenocarcinoma.
-
Cassava A20/AN1 Genes Under Abiotic Stress
2026-09-22
This study shows that cassava Metip4, Metip8, and Metip11 broadly promote tolerance to drought, salinity, temperature extremes, and manganese stress, while differing in responses to cadmium and copper. By combining genetic, cellular, physiological, and transcriptomic approaches, the work provides evidence for both functional convergence and gene-specific specialization within the cassava A20/AN1 family.
-
Bufuralol Hydrochloride in Organoid Assays
2026-09-22
Bufuralol hydrochloride connects β-receptor pharmacology with human intestinal organoid workflows for studying exposure, transport, and metabolism. This guide outlines a practical 3D-to-2D assay strategy, concentration screening plan, and troubleshooting framework that separates true β-adrenergic effects from vehicle, maturity, and barrier artifacts.
-
MAPK10–KRT16 Signaling in NSCLC Metastasis
2026-09-21
The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical analyses position the MAPK10/KRT16/RNF213 axis as a mechanistic framework for studying NSCLC dissemination and as a candidate prognostic pathway.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-21
Wang et al. identify a METTL16–SENP3–LTF regulatory axis that links m6A-dependent RNA regulation with SUMOylation, iron handling, and ferroptosis resistance in hepatocellular carcinoma. The study combines cell, organoid, xenograft, genetically engineered mouse, biochemical, and human-sample analyses to establish this axis as a mechanistic driver of tumor progression and a potential sensitization target.
-
SkQ1, Mitochondrial Apoptosis, and Muscle Atrophy
2026-09-20
The reference study used a time-resolved ovarian cancer model and chronic mitochondrial antioxidant treatment to test whether mitochondrial hydrogen peroxide, apoptosis, or necroptosis drives skeletal muscle atrophy. SkQ1 normalized late-stage mitochondrial peroxide emission and caspase-9/-3 activity without restoring type IIB fibre size, challenging a simple causal model of mitochondrial oxidative stress–dependent muscle loss.
-
25-Hydroxycholesterol Reprograms TAM Immunity
2026-09-19
Xiao et al. identify CH25H-derived 25-hydroxycholesterol (25HC) as an immunometabolic checkpoint in tumor-associated macrophages. The study links lysosomal 25HC accumulation to GPR155–mTORC1 inhibition, AMPKα activation, STAT6 phosphorylation, and ARG1-dependent immunosuppression, while showing that CH25H targeting can improve anti-tumor responses with or without anti-PD-1 therapy.
-
Tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology
2026-09-18
Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated species that increases with Alzheimer’s disease progression and is frequently found in neurofibrillary tangles. Their ex vivo experiments further show that NUAK inhibition with WZ4003 lowers p-tau Ser356 in human brain slices, while producing broader and potentially damaging protein changes in postnatal mouse cultures.
-
Tofacitinib Workflows for RA Macrophage Research
2026-09-18
Tofacitinib (CP-690550) enables researchers to connect JAK/STAT-dependent cytokine signaling blockade with macrophage metabolism, mitochondrial structure, and inflammatory phenotype. This practical workflow combines dose-response testing, phospho-STAT5 analysis, cytokine profiling, and mitochondrial readouts to distinguish pathway inhibition from broader immune-cell stress.